Verekitug  (Synonyms: ASP-7266; TRAB-1; UPB-101)

Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Verekitug binds human TSLPR with subpicomolar affinity, inhibits TSLP binding to TSLPR, and shows superior potency in TSLP-driven functional assays compared to the reference drug tezepelumab^[1].
Verekitug potently inhibits TSLP-induced proliferation of Ba/F3 cells expressing human TSLPR at ~6-fold the potency of a benchmark anti-TSLP antibody, and inhibits TSLP-induced TARC expression by human PBMCs at ~4-fold the potency of a benchmark anti-TSLP antibody^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

64109  [NCBI]

Q9HC73

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144 kDa

2768386-15-6

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Verekitug on AHC2 biosensor, can bind TSLP R Protein, Human (HEK293, His, HY-P71389) with an affinity constant of 1.847E-10 M as determined in BLI assay.

• [1]. Singh D, et al. Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial. Clin Pharmacol Ther. 2026;119(3):782-790.  [Content Brief]

  [2]. Komori HK, et al. Potential of alarmin-targeted bispecific and combination therapies in airway disease. Front Allergy. 2025;6:1700060. Published 2025 Dec 2.  [Content Brief]

  [3]. Hansi RK, et al. Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets. Biomedicines. 2024;12(10):2312. Published 2024 Oct 11.  [Content Brief]